Infervision vs Riverain Technologies
Both detect lung nodules on chest imaging as concurrent read tools, available alongside the radiologist's initial read rather than after it, so the split is breadth and regulatory reach against evidence you can inspect and a deployment that stays inside your institution. If you want the widest coverage and multi jurisdiction footprint, start with Infervision, which spans the widest scope in the imaging lane, but its published performance evidence is thin and it is China headquartered, which raises cross border data questions. If you want a focused lung nodule tool with an inspectable clearance record and imaging that stays on premise, start with Riverain, accepting an older and narrower product. Infervision is cleared across five regulatory regimes. Riverain was the first device cleared for concurrent reading.
- The widest scope in the imaging lane: lung CT, chest radiography, and coronary CTA detection plus surgical planning across thorax, liver, and urology and standardized tumor response assessment, far beyond Riverain's cardiothoracic focus.
- The broadest multi jurisdiction footprint in the index: cleared across the US FDA, European CE, UK UKCA, Japan PMDA, and China NMPA, with iterative US clearances including 4 mm nodule detection.
- Long running deployment at scale, more than 380 sites processing over 55,000 cases daily, including UN procured tuberculosis screening in low resource settings.
- An inspectable clearance record: performance broken out by nodule type, residual analysis across slice thickness, and a site configurable micro nodule threshold, where Infervision publishes no sensitivity, specificity, or reader study data at all.
- A distinct technical mechanism: deep learning vessel suppression that alters the image so both the algorithm and the human read better, cleared in 2016 as the first device supporting concurrent reading, with a multi reader study reporting a 29 percent reduction in missed actionable nodules.
- A deployment that keeps imaging inside the institution: it installs without new hardware and likely on premise, an advantage for buyers with data residency constraints, and it is US headquartered.
Side-by-Side
| Axis | I Infervision |
R Riverain Technologies |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Both detect lung nodules on chest imaging as concurrent read tools, available alongside the radiologist's initial interpretation rather than after it, which trades faster workflow for greater exposure to automation bias, the opposite of a second read design. Infervision is the weaker on evidence despite its scale: no peer reviewed reader study, accuracy paper, or outcome data was located for any product in its line, and scale of use is not evidence of benefit, which matters most for its 4 mm nodule claim where false positive rates rise sharply. It is China headquartered and processes US and European imaging, so cross border data transfer terms are a live procurement question its materials do not address. Riverain is an older generation of authorization with a narrow cardiothoracic scope, and its foundational clearance predates current standards such as Predetermined Change Control Plans. Neither publishes pricing or a security attestation.